Form D · Pharmaceuticals
Paragon Biosciences Qlarity Capital, Inc.
Chicago, IL · CIK 0001793485
Offering snapshot reported Nov 12, 2019 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $15M Reported outside-investor minimum
- First sale
- Oct 25, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 12, 2019 | Initial | $15,000,001 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $450K
- Finders' fees
- $0
- Form D file number
- 021-353125
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Paragon Health Capital, LLC | 300729 |
Source: Form D, filed Nov 12, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey S. Aronin | Director |
| Antonio J. Gracias | Director |
| Patrick J. Morris | Director, Executive |
| Darien Parhad | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
330 N. Wabash Ave., Ste. 3500
Chicago, IL, 60611
Chicago, IL, 60611